Cortexyme Financial Statements () |
||||||||||
Cortexymesmart-lab.ru | % | 2017 | 2018 | 2019 | 2020 | 2021 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 31.12.2017 | 31.12.2018 | 16.03.2020 | 01.03.2021 | 01.03.2022 | 09.08.2022 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
Operating Income, bln rub | -10.4 | -12.1 | -39.2 | -78.9 | -89.9 | -149.4 | ||||
EBITDA, bln rub | ? | -10.5 | -11.5 | -39.2 | -78.9 | -90.3 | -83.5 | |||
Net profit, bln rub | ? | -12.2 | -12.5 | -37.0 | -76.8 | -89.9 | -149.9 | |||
OCF, bln rub | ? | -9.83 | -11.7 | -33.3 | -50.8 | -62.9 | -47.9 | |||
CAPEX, bln rub | ? | 0.077 | 0.212 | 0.055 | 0.052 | 0.180 | 0.049 | |||
FCF, bln rub | ? | -9.90 | -11.9 | -33.3 | -50.9 | -63.1 | -47.9 | |||
Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | ||||||
Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
OPEX, bln rub | 10.4 | 12.1 | 39.2 | 78.9 | 90.3 | 150.1 | ||||
Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
R&D, bln rub | 9.10 | 10.1 | 30.2 | 61.3 | 60.8 | 94.8 | ||||
Interest expenses, bln rub | 1.64 | 0.957 | 0.000 | 0.000 | 0.000 | 0.662 | ||||
Assets, bln rub | 7.72 | 72.9 | 124.4 | 189.5 | 133.2 | 117.9 | ||||
Net Assets, bln rub | ? | -20.3 | 71.4 | 115.5 | 172.3 | 118.6 | 111.5 | |||
Debt, bln rub | 7.17 | 0.000 | 0.000 | 0.208 | 0.420 | 0.133 | ||||
Cash, bln rub | 7.34 | 71.7 | 99.9 | 133.8 | 106.8 | 94.7 | ||||
Net debt, bln rub | -0.17 | -71.7 | -99.9 | -133.6 | -106.4 | -94.5 | ||||
Ordinary share price, rub | 56.1 | 27.8 | 12.6 | 2.22 | ||||||
Number of ordinary shares, mln | 21.6 | 21.6 | 19.1 | 29.2 | 29.8 | 32 467 | ||||
Market cap, bln rub | 0 | 0 | 1 070 | 811 | 376 | 72 077 | ||||
EV, bln rub | ? | 0 | -72 | 970 | 677 | 269 | 71 982 | |||
Book value, bln rub | -20 | 71 | 115 | 172 | 119 | 105 | ||||
EPS, rub | ? | -0.57 | -0.58 | -1.94 | -2.63 | -3.02 | 0.00 | |||
FCF/share, rub | -0.46 | -0.55 | -1.75 | -1.74 | -2.12 | 0.00 | ||||
BV/share, rub | -0.94 | 3.31 | 6.06 | 5.90 | 3.98 | 0.00 | ||||
FCF yield, % | ? | -3.11% | -6.28% | -16.8% | -0.07% | |||||
ROE, % | ? | 60.3% | -17.5% | -32.0% | -44.6% | -75.8% | -134.4% | |||
ROA, % | ? | -158.5% | -17.1% | -29.7% | -40.6% | -67.5% | -127.2% | |||
P/E | ? | 0.00 | 0.00 | -28.9 | -10.5 | -4.18 | -480.7 | |||
P/FCF | 0.00 | 0.00 | -32.1 | -15.9 | -5.95 | -1 505 | ||||
P/BV | ? | 0.00 | 0.00 | 9.27 | 4.71 | 3.17 | 687.7 | |||
EV/EBITDA | ? | 0.02 | 6.25 | -24.8 | -8.58 | -2.98 | -861.6 | |||
Debt/EBITDA | 0.02 | 6.25 | 2.55 | 1.69 | 1.18 | 1.13 | ||||
R&D/CAPEX, % | 11 817% | 4 757% | 54 935% | 117 898% | 33 775% | 193 447% | ||||
Cortexyme shareholders |